One year in review
Novel insights into the management of rheumatoid arthritis: one year in review 2022
C. Garaffoni1, A. Adinolfi2, A. Bortoluzzi3, G. Filippou4, A. Giollo5, G. Sakellariou6, S. Sirotti7, N. Ughi8, C.A. Scirè9, E. Silvagni10
- Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S. Anna, Cona, Ferrara, Italy.
- Rheumatology Division, Multispecialist Medical Department, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
- Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S. Anna, Cona, Ferrara, Italy.
- Rheumatology Unit, Luigi Sacco University Hospital, Milano, Italy.
- Rheumatology Unit, Department of Medicine, University of Padova, Italy.
- Department of Internal Medicine and Medical Therapy, University of Pavia, and Istituti Clinici Scientifici Maugeri IRCCS Pavia, Italy.
- Rheumatology Unit, Luigi Sacco University Hospital, Milano, and Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Italy.
- Rheumatology Division, Multispecialist Medical Department, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
- School of Medicine and Surgery, University of Milano-Bicocca, Milan, and Epidemiology Unit, Italian Society for Rheumatology, Milan, Italy. carlo.scire@unimib.it
- Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S. Anna, Cona, Ferrara, Italy.
CER15853
2022 Vol.40, N°7
PI 1247, PF 1257
One year in review
Free to view
(click on article PDF icon to read the article)
PMID: 35801648 [PubMed]
Received: 16/05/2022
Accepted : 14/06/2022
In Press: 04/07/2022
Published: 04/07/2022
Abstract
New evidence for the treatment of rheumatoid arthritis (RA) has emerged during the last year. Specifically, updated guidelines on pharmacological and non-pharmacological management of RA have emphasised the necessity of global patient’s care, and have shifted the role of some older drugs, such as glucocorticoids and methotrexate. In addition, the long-term safety of Janus kinase inhibitors was investigated and reinforced. With respect to the coronavirus-19 pandemic, reassuring data on the efficacy and safety of vaccinations in the RA population were acquired, as well as on the potential role of telemedicine in RA management. Machine learning prediction models and biomarkers development have emerged as promising innovations in the area of precision/personalised medicine, appearing to encourage future expansion. In this narrative review, the authors aim to give their specific point of view on the most relevant and potentially impacting novelties published during 2021 and early 2022 in the context of RA management.
